Tim DraperFounder and Managing Partne, Draper Associate · I back the ideas that look crazy first

Tim asked the question, EYWA didn’t hesitate! #startup

15 Oct 2026 · 1 min

Watch on YouTube

1:02

In a brief interview, Tim Draper questions the founders of EYWA about their biotech platform that engineers microorganisms to biosynthesize psychedelic compounds—psilocybin, DMT, and 5‑MeO‑DMT. EYWA reports a 20‑fold increase in psilocybin yield since receiving investment and highlights a fast‑track regulatory pathway that could allow US sales within 12 months. The founders state that achieving this timeline depends on raising an additional $1 million, after which the product would be distributed as a doctor‑prescribed therapy rather than an over‑the‑counter shelf product.

Ewa, I love what you're doing for mental health. I loved all of the others in
therapy. And just a month ago, they announced a fast track for approval 12 months from now. The science is ready, but the supply is not. Today, no one can combine pharma-grade IP, scale, precision, and access all together. But with biotechnology, we can do this. From Latin America to the world, we engineered our own microorganisms with biosynthesis and bioinformatics to produce psilocybin, DMT, and 5-MeO-DMT. Since our investment, we have done amazing progress. Thank you, Tim. We did a 20x on our psilocybin yield.
Will you be able to sell your psilocybin 12 months from now in the US?
Yes. Wow.
Well, that's exciting.
If we raise $1 more million.
Will it be doctor prescribed or will it be on the shelf?
It will be doctor prescribed and directly to clinics or distributors, depending on the state.